The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters
Open accessAbstract
Since metabolic process differs between humans and mice, studies were performed in hamsters, which are generally considered to be a more appropriate animal model for studies of obesity-related metabolic disorders. The modulation of gut microbiota, bile acids and the farnesoid X receptor (FXR) axis is correlated with obesity-induced insulin resistance and hepatic steatosis in mice. However, the interactions among the gut microbiota, bile acids and FXR in metabolic disorders remained largely unexplored in hamsters. In the current study, hamsters fed a 60% high-fat diet (HFD) were administered vehicle or an antibiotic cocktail by gavage twice a week for four weeks. Antibiotic treatment alleviated HFD-induced glucose intolerance, hepatic steatosis and inflammation accompanied with decreased hepatic lipogenesis and elevated thermogenesis in subcutaneous white adipose tissue (sWAT). In the livers of antibiotic-treated hamsters, cytochrome P450 family 7 subfamily B member 1 (CYP7B1) in the alternative bile acid synthesis pathway was upregulated, contributing to a more hydrophilic bile acid profile with increased tauro- β -muricholic acid (T β MCA). The intestinal FXR signaling was suppressed but remained unchanged in the liver. This study is of potential translational significance in determining the role of gut microbiota-mediated bile acid metabolism in modulating diet-induced glucose intolerance and hepatic steatosis in the hamster.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richness of human gut microbiome correlates with metabolic markers
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.-M., Kennedy, S., et al. (2013) · Nature · doi:10.1038/nature12506 · Cited by 4,662
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Diet–microbiota interactions as moderators of human metabolism
Sonnenburg, J. L., & Bäckhed, F. (2016) · Nature · doi:10.1038/nature18846 · Cited by 2,257
Kovatcheva-Datchary, P., Nilsson, A., Akrami, R., Lee, Y. S., De Vadder, F., Arora, T., Hallen, A., Martens, E., Björck, I., & Bäckhed, F. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.10.001 · Cited by 1,731
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422
Anhê, F. F., Roy, D., Pilon, G., Dudonné, S., Matamoros, S., Varin, T. V., Garofalo, C., Moine, Q., Desjardins, Y., Levy, E., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-307142 · Cited by 1,137
Jones, B. V., Begley, M., Hill, C., Gahan, C. G. M., & Marchesi, J. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804437105 · Cited by 1,098
The role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020 · cited 1×
“com/locate/apsb Acta Pharmaceutica Sinica B Acta Pharmaceutica Sinica B 2019;9(4):702–710”
BackgroundGut Microbiota Orchestrates Energy Homeostasis during Cold
Chevalier, C., Stojanović, O., Colin, D. J., Suarez-Zamorano, N., Tarallo, V., Veyrat-Durebex, C., Rigo, D., Fabbiano, S., Stevanović, A., Hagemann, S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.004 · Cited by 829
Cited by
The role of the gut microbiome and its metabolites in metabolic diseases
Wu, J., Wang, K., Wang, X., Pang, Y., & Jiang, C. (2021) · Protein & Cell · doi:10.1007/s13238-020-00814-7 · Cited by 557
Self-citationThe links between gut microbiota and obesity and obesity related diseases
Geng, J., Ni, Q., Sun, W., Li, L., & Feng, X. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112678 · Cited by 399
Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway
Nie, Q., Luo, X., Wang, K., Ding, Y., Jia, S., Zhao, Q., Li, M., Zhang, J., Zhuo, Y., Lin, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.03.034 · Cited by 326
Self-citationKuang, J., Wang, J., Li, Y., Li, M., Zhao, M., Ge, K., Zheng, D., Cheung, K. C. P., Liao, B., Wang, S., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.011 · Cited by 321
GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
Abdalqadir, N., & Adeli, K. (2022) · Microorganisms · doi:10.3390/microorganisms10102061 · Cited by 119
Chen, M., Guo, W.-L., Li, Q.-Y., Xu, J.-X., Cao, Y.-J., Liu, B., Yu, X.-D., Rao, P.-F., Ni, L., & Lv, X.-C. (2020) · Food & Function · doi:10.1039/c9fo03003d · Cited by 77
Self-citationMolecular Biomarkers for Gestational Diabetes Mellitus and Postpartum Diabetes
Lu, W., & Hu, C. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002160 · Cited by 52
Zhang, Q., Fan, X.-Y., Guo, W.-L., Cao, Y.-J., Lin, Y.-C., Cheng, W.-J., Chen, L.-J., Rao, P.-F., Ni, L., & Lv, X.-C. (2020) · Food & Function · doi:10.1039/d0fo00065e · Cited by 42
Metadata
- Authors
- Sun, L., Pang, Y., Wang, X., Wu, Q., Liu, H., Liu, B., Liu, G., Ye, M., Kong, W., & Jiang, C.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 9
- Issue
- 4
- Pages
- 702-710
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W2912816189
- Cited by
- 204
- References
- 17
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.